About Exicure
Exicure is a company based in Skokie (United States) founded in 2009. Exicure has raised $72.29 million across 12 funding rounds from investors including AbbVie, Illumina and Aon. The company has 7 employees as of December 31, 2024. Exicure offers products and services including SNA Platform. Exicure operates in a competitive market with competitors including Biogen, Denali Therapeutics, ADMA Biologics, Kymeratx and Poseida Therapeutics, among others.
- Headquarter Skokie, United States
- Employees 7 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exicure, Inc.
-
Annual Revenue
$500 K (USD)0as on Dec 31, 2024
-
Net Profit
-$9.7 M (USD)42.65as on Dec 31, 2024
-
EBITDA
-$4.13 M (USD)67.52as on Dec 31, 2024
-
Total Equity Funding
$72.29 M (USD)
in 12 rounds
-
Latest Funding Round
$1.3 M (USD), Post-IPO
Nov 01, 2024
-
Investors
AbbVie
& 15 more
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Exicure
Exicure is a publicly listed company on the NASDAQ with ticker symbol XCUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Exicure
Exicure offers a comprehensive portfolio of products and services, including SNA Platform.
Platform for creating nucleic acid therapies targeting diseases
Funding Insights of Exicure
Exicure has successfully raised a total of $72.29M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.3 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Exicure
Exicure has secured backing from 16 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include AbbVie, Illumina and Aon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Venture capital investing and portfolio management services for accredited investors.
|
Locked | Locked | Locked | |
|
Climate solutions are advanced via venture capital and startup acceleration.
|
Locked | Locked | Locked |
Investor details for Exicure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exicure
Investment portfolio details for Exicure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Exicure
Detailed financials for Exicure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exicure Comparisons
Peer comparison for Exicure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exicure
Exicure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, ADMA Biologics, Kymeratx and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of Exicure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exicure
Complete news archive for Exicure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exicure
Exicure was founded in 2009.
Exicure is headquartered in Skokie, United States. It is registered at Skokie, Illinois, United States.
Exicure is a funded company, having raised a total of $72.29M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Exicure is 7.
Annual revenue of Exicure is $500K as on Dec 31, 2024.
Exicure was founded in 2009 in Skokie, United States, within the biotechnology sector. A platform based on spherical nucleic acid (SNA) technology is employed to create immunomodulatory and gene silencing drugs targeting validated pathways. A pipeline of candidates is advanced for applications in oncology, such as solid tumors, and immunology, including psoriasis and inflammatory disorders. Operations focus on therapeutic development for these disease areas.
Exicure's top competitors include ADMA Biologics, Juno Therapeutics and BioNTech.
Exicure offers SNA Platform.
Yes, Exicure is publicly traded on NASDAQ under the ticker symbol XCUR.
Exicure has 16 investors. Key investors include AbbVie, Illumina, Aon, Groupon, and Luye Pharma.
The ticker symbol of Exicure is XCUR on NASDAQ.